Pamelor (nortriptyline) is classified as what type of antidepressant?

Pamelor, also known as nortriptyline, is classified as a tricyclic antidepressant (TCA). This classification is based on its chemical structure, which consists of three rings, hence the name "tricyclic." TCAs primarily work by inhibiting the reuptake of norepinephrine and serotonin in the brain, which increases the availability of these neurotransmitters and helps improve mood in individuals with depression.

The effectiveness of tricyclic antidepressants is well-documented, particularly for major depressive disorder and anxiety disorders. However, they are also associated with a range of potential side effects, which can include sedation, weight gain, and anticholinergic effects, due to their broader impact on neurotransmitter systems.

In contrast, selective serotonin reuptake inhibitors (SSRIs) specifically target serotonin reuptake, monoamine oxidase inhibitors (MAOIs) work by inhibiting the breakdown of neurotransmitters, and atypical antidepressants do not fit neatly into the other categories and generally have varied mechanisms of action. Each of these other classes has different implications for use and side effect profiles compared to TCAs like nortriptyline.